Abstract
Background Uptake of breast cancer screening has been decreasing in England since 2007, and may increase proportional incidence of nonscreened cancers. However, recent trends in proportional incidence and net-survivals of screened and nonscreened breast cancers are unclear.
Methods We extracted population-based proportional incidence and age-standardized 5-year net-survivals from Public Health England, for English women with invasive breast cancer diagnosed during 1995-2011 (linked to death certificates, followed through 2016). Piecewise log-linear models with change-point/joinpoint were used to estimate temporal trends. We conducted a quasi-experimental study to test the hypothesis that the trend-change year of proportional incidence coincided with that of 5-year net-survival.
Results Among 254,063 women in England with invasive breast cancer diagnosed during 1995-2011, there was downward-to-upward trend-change in proportional incidence of nonscreened breast cancers (annual percent change[APC]=5.6 after 2007 versus APC=-3.5 before 2007, P<0.001) in diagnosis-year 2007, when steeper upward-trend in age-standardized 5-year net survival started (APC=5.7 after 2007/2008 versus APC=0.3 before 2007/2008, P<0.001). Net-survival difference of screened versus nonscreened cancers also significantly narrowed (18% in 2007/2008 versus 5% in 2011). Similar associations were found in all strata of race, cancer stage, grade and histology, except in Black patients or patients with stage I, stage III, or grade I cancer.
Conclusions The downward-to-upward trend-change in proportional incidence of nonscreened breast cancers is associated with steeper upward-trend in age-standardized 5-year net survival among English women in recent years. Survival benefits of breast cancer screening appear decreasing in recent years. The data support reduction of breast cancer screening in some patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
None
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Not Applicable
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
We cannot share the original data which are confidential, and were obtained with review and approval from the Public Health England.
